Federated Hermes
XENE icon

Federated Hermes’s Xenon Pharmaceuticals XENE Stock Holding History

Federated Hermes’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.3M Sell
883,737
-88,500
-9% -$4.91M 0.08% 260
2026
Q1 		$56.5M Buy
972,237
+300,000
+45% +$13.8M 0.09% 235
2025
Q4 		$30.1M Buy
672,237
+439,737
+189% +$18.5M 0.05% 360
2025
Q3 		$9.33M Hold
232,500
– – 0.02% 583
2025
Q2 		$7.28M Hold
232,500
– – 0.01% 639
2025
Q1 		$7.8M Sell
232,500
-326,000
-58% -$12.4M 0.02% 611
2024
Q4 		$21.9M Sell
558,500
-177,700
-24% -$7.35M 0.05% 393
2024
Q3 		$29M Buy
736,200
+1,645
+0.2% +$66.3K 0.06% 345
2024
Q2 		$28.6M Sell
734,555
-345
-0% -$13.8K 0.07% 319
2024
Q1 		$31.6M Buy
734,900
+388,304
+112% +$17.9M 0.07% 316
2023
Q4 		$16M Buy
+346,596
New +$12.2M 0.04% 443

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Federated Hermes's XENE Position: Q2 2026 in Review

Federated Hermes reduced its Xenon Pharmaceuticals (XENE) stake by 9.1% in Q2 2026, selling an estimated $4.91M and leaving 883,737 shares worth $53.3M. The position accounts for 0.08% of the portfolio, ranked #260.

Federated Hermes first reported a position in XENE in Q4 2023 and has held it in 11 quarters since. The position peaked at $56.5M in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Federated Hermes held 883,737 shares of Xenon Pharmaceuticals worth $53.3M as of Q2 2026.
  • Federated Hermes sold 88,500 Xenon Pharmaceuticals shares in Q2 2026, an estimated $4.91M.
  • Xenon Pharmaceuticals made up 0.08% of Federated Hermes's portfolio in Q2 2026, its #260 holding.
  • Federated Hermes first reported a position in Xenon Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Federated Hermes's Xenon Pharmaceuticals position peaked at $56.5M in Q1 2026.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.